The innovative Drug Aliqopa launched by Bayer AG’s is expected to propel the Follicular Lymphoma Treatment Market growth
Some of the key players operating in the global follicular lymphoma treatment market include Roche, Spectrum Pharmaceuticals, Johnson and Johnson, CTI Biopharma, Celgene, AbbVie Inc., Novartis, Amgen, Merck & Co. (MRK), Seattle Genetics, Pharmacyclics/ Bristol-Myers Squibb (BMY), and Bayer AG’S. In 2017, Bayer AG’s has launched an innovative drug, Aliqopa, also known as copanlisib, which is a kinase inhibitor that block certain enzymes responsible in promoting cell growth.
Rituximab a monoclonal antibody used as a therapeutic agent is expected to augment the Follicular Lymphoma Treatment Market growth
The major factors contributing to the growth of global follicular lymphoma treatment market are rising adoption of monoclonal antibodies for targeted therapies. According to the National Center for Biotechnology Information (NCBI), in 2016, monoclonal antibodies are considered as the successful therapeutics in the cancer treatment. The use of monoclonal antibodies is expected to overcome the side effects, which are generally exhibited by traditional therapies such as radiation and chemotherapy. Therefore, the monoclonal antibody such as rituximab, an anti-CD20 antibody can act as a potential therapeutic agent for the treatment of follicular lymphoma cancer.
Moreover, increase in the number of incidence of relapsed follicular lymphoma is also expected to drive the market growth as the number of relapse for the disease results in the same patient availing the treatment multiple times. However, the factors hindering the growth of follicular lymphoma treatment market are the availability of the drugs and high cost of the treatment.
Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/907
Rising prevalence of follicular lymphoma cases is expected to fuel the market growth in North America
On the basis of geography, the global follicular lymphoma treatment market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global follicular lymphoma treatment market, owing to the rise in the follicular lymphoma cases. According to the American Cancer Society (ACS), in 2017, around 72,240 people including adults and children are expected to get diagnosed with follicular lymphoma.
Moreover, a series of studies are initiated in the National Cancer Institute, in U.S., to assess the novel emerging sequencing technologies in cancer, as part of the cancer genome characterization. Furthermore, Asia Pacific is expected to hold a major market share in the global follicular lymphoma treatment market over the forecast period. This is mainly owing to advanced research practices adopted by the government and private research institutes of China to curb the follicular lymphoma cancer.